Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Industry News

Genomadix Inc. Announces Health Canada License for Rapid Genetic Test to Aid Therapy Selection for Stroke and Cardiovascular Disease Patients

January 30, 2025

News Industry News

Affera, Inc. Announces Successful First-In-Human Use of SpherePVI Circumferential Pulmonary Vein Isolation Device Using Pulsed Field Energy

July 27, 2021

News Industry News

Conformal Medical's CLAAS® Stroke Prevention Technology Announces Promising Clinical Results at 2020 TCT Conference

October 15, 2020

News Industry News

Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke

September 05, 2018

News Industry News

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

January 29, 2018

News Industry News

Neuravi Announces Completion of Patient Enrollment in Clinical Trial of a Novel Stent Retriever for Acute Ischemic Stroke

February 21, 2017

News Industry News TCT 2016

Long-Term Study Results Show that PFO Closure is More Effective Than Medical Management in Preventing Recurrent Stroke

November 01, 2016

News Industry News

Neuravi Announces European Launch of EmboTrap II Stent Retriever for the Treatment of Acute Stroke

September 08, 2016

News Industry News

Silk Road Medical Announces CE Mark Approval and First Patients Treated with the Next Generation ENROUTE® Transcarotid Neuroprotection System

March 16, 2016

News Industry News

Neuravi Announces First Patient Treated in International Pivotal Clinical Trial of Novel Stent Retriever for Acute Ischemic Stroke

November 04, 2015

News Industry News

First Patient Successfully Enrolled into ROADSTER 2 Transcarotid Artery Revascularization (TCAR) Study

November 02, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Industry News

Pre-Clinical Study Conducted at Mayo Clinic LOS ANGELES, NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company, today announced that results of an animal study of its Thin Film Nit

May 04, 2015

Advertisement

Genomadix Inc. Announces Health Canada License for Rapid Genetic Test to Aid Therapy Selection for Stroke and Cardiovascular Disease Patients

Affera, Inc. Announces Successful First-In-Human Use of SpherePVI Circumferential Pulmonary Vein Isolation Device Using Pulsed Field Energy

Conformal Medical's CLAAS® Stroke Prevention Technology Announces Promising Clinical Results at 2020 TCT Conference

Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

Neuravi Announces Completion of Patient Enrollment in Clinical Trial of a Novel Stent Retriever for Acute Ischemic Stroke

Long-Term Study Results Show that PFO Closure is More Effective Than Medical Management in Preventing Recurrent Stroke

Neuravi Announces European Launch of EmboTrap II Stent Retriever for the Treatment of Acute Stroke

Silk Road Medical Announces CE Mark Approval and First Patients Treated with the Next Generation ENROUTE® Transcarotid Neuroprotection System

Neuravi Announces First Patient Treated in International Pivotal Clinical Trial of Novel Stent Retriever for Acute Ischemic Stroke

First Patient Successfully Enrolled into ROADSTER 2 Transcarotid Artery Revascularization (TCAR) Study

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Pre-Clinical Study Conducted at Mayo Clinic LOS ANGELES, NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company, today announced that results of an animal study of its Thin Film Nit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content